A
SPRB

Abingworth’s Spruce Biosciences SPRB Stock Holding History

Abingworth’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.97M Hold
23,900
– – 0.64% 13
2022
Q3 		$2.47M Buy
+23,900
New +$3.34M 0.85% 12

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth's SPRB Position: Q4 2022 in Review

Abingworth held its Spruce Biosciences (SPRB) position steady in Q4 2022 at 23,900 shares worth $1.97M. The position accounts for 0.64% of the portfolio, ranked #13.

Abingworth first reported a position in SPRB in Q3 2022 and has held it in 2 quarters since. The position peaked at $2.47M in Q3 2022. 29 funds tracked by Wall St. Rank hold SPRB as of Q4 2022.

  • Abingworth held 23,900 shares of Spruce Biosciences worth $1.97M as of Q4 2022.
  • Abingworth left its Spruce Biosciences share count unchanged in Q4 2022.
  • Spruce Biosciences made up 0.64% of Abingworth's portfolio in Q4 2022, its #13 holding.
  • Abingworth first reported a position in Spruce Biosciences in Q3 2022 and has held it in 2 quarters since.
  • Abingworth's Spruce Biosciences position peaked at $2.47M in Q3 2022.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.